Previous Close | 30.50 |
Open | 30.36 |
Bid | 28.85 x 900 |
Ask | 30.00 x 800 |
Day's Range | 29.05 - 30.36 |
52 Week Range | 26.85 - 65.09 |
Volume | |
Avg. Volume | 766,230 |
Market Cap | 1.465B |
Beta (5Y Monthly) | 0.97 |
PE Ratio (TTM) | 17.19 |
EPS (TTM) | 1.71 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 41.21 |
Subscribe to Yahoo Finance Plus to view Fair Value for EBS
The FDA issued a warning letter to Emergent BioSolutions Inc (NYSE: EBS), citing certain deficiencies at the company's troubled manufacturing facility in Baltimore, Maryland. The FDA pointed to equipment cleaning and maintenance deficiencies to prevent drug product contamination. Reuters reported that the agency also recommended that the company review its quality control process. Related: Emergent Bio Says Johnson & Johnson Breached COVID-19 Vaccine Contract. Emergent had said the FDA had last
The FDA pointed to deficiencies in cleaning and maintenance of equipment to prevent contamination of drug product and also recommended the company review its quality control process, Emergent said. Earlier in August, Emergent had said the FDA had last inspected its facility at Camden in February and was waiting for the agency's feedback.
GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: 12th Annual Midwest IDEAS Investor ConferenceChicago, ILAugust 24, 2022 – presentation scheduled at 5:15 PM central time https://www.wsw.com/webcast/threepa38/ebs/2021448 Wells Fargo 2022 Healthcare ConferenceBoston, MASeptember 8, 2022 – fireside chat scheduled at 9:10 AM easter